## INTERNATIONAL SEARCH REPORT

Internal Application No PC1/EP2004/051522

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K39/108 A61K39/112 C07K14/25 C07K14/245

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SHEORAN ABHINEET S ET AL: "Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants."  INFECTION AND IMMUNITY, JUN 2003, vol. 71, no. 6, June 2003 (2003–06), pages 3125–3130, XP002301428 ISSN: 0019–9567 page 3125, right-hand column, paragraph 2 page 3126, right-hand column, paragraph 5; figure 1  -/  *Special categories of cited documents:  *A' document defining the general state of the art which is not considered to be of particular relevance in the considered to be of particular relevance which read through the provided and column to the considered to involve an inventive step when the document later than the provided are claimed  **Cocument published prior to the international filing date but later than the priority date claimed  **Cocument published prior to the international filing date but later than the priority date claimed  **Cocument published prior to the international filing date but later than the priority date claimed  **Cocument published prior to the international filing date but later than the priority date claimed  **Cocument published prior to the international filing date but later than the priority date claimed  **Cocument published prior to the international filing date but later than the priority date claimed  **Cocument published prior to the international filing date but later than the priority date claimed  **Cocument published prior to the international filing date but later than the priority date claimed  **Cocument published prior to the international filing date but later than the priority date claimed  **Cocum				
C. DOCUMENTS CONSIDERED TO BE RELEVANT  Category* Citation of document, with indication, where appropriate, of the relevant passages  SHEORAN ABHINEET S ET AL: "Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants."  INFECTION AND IMMUNITY, JUN 2003, vol. 71, no. 6, June 2003 (2003-06), pages 3125-3130, XP002301428  ISSN: 0019-9567  page 3126, right-hand column, paragraph 2 - page 3126, right-hand column, paragraph 5; figure 1  -/  * Special categories of cited documents:  ** document defining the general state of the at which is not considered to be of particular relevance  ** are active document but published on or after the international fling date of the state of the special reason (as specialed)  ** of document mortaring to an oral disclosure, use, exhibition or which is action or other special reason (as specialed)  **Officerement published after the international fling date of the continuation of the international fling date or priority date and not in conflict with the application but reveal to the state of the published on after the international fling date or which is action or exhibition or other special reason (as specialed)  **Colument of particular relevance the claimed invention cannot be considered to over one other such documents, such combination being obvious to a person skilled in earth in the published on after the international fling date out which is action or other special reason (as specialed)  **Colument of particular relevance; the claimed invention cannot be considered to remain and colument is combined with one or more other such documents, such combination being obvious to a person skilled in earth in the material and the priority date claimed.  **Document of particular relevance; the claimed invention cannot be considered over or one other such documents, such combination being obvious to a person skilled in the art.  **A document of particular relevance; the claimed invention cannot be considered over or				
X  SHEORAN ABHINEET S ET AL: "Stx2—specific human monocional antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants."  INFECTION AND IMMUNITY. JUN 2003, vol. 71, no. 6, June 2003 (2003–06), pages 3125–3130, XP002301428  ISSN: 0019–9567  page 3125, right—hand column, paragraph 2 — page 3126, right—hand column, paragraph 5; figure 1  -/  *Special categories of cited documents:  *A' document defining the general state of the an which is not considered to be of particular relevance its ling date of the continuation of the mans of the remains of the research of the special reason (as specified) of another coller nor other means  *Coursent which may throw doubts an priority, claim(s) or other means  *Coursent referring to an oral disclosure, use, exhibition or other means  *P' document published prior to the international filing date but start frain the priority date claimed  *P' document published prior to the international filing date but start frain the priority date claimed  *P' document published prior to the international filing date but start frain the priority date claimed  *P' document published prior to the international filing date but start frain the priority date claimed  *P' document published prior to the international filing date but start frain the priority date claimed  *P' document published prior to the international filing date but start frain the priority date claimed  *P' document published prior to the international filing date but start frain the priority date claimed  *A' document member of the same patent family  *Date of the actual completion of the international search  19 October 2004  Name and mailing address of the ISA  European Patent Cifice, P.B. 5818 Patentilaan 2  **Name and mailing address of the ISA  **European Patent Cifice, P.B. 5818 Patentilaan 2  **L' 2004  **Authorized officer  **Authorized officer		out har, broots, onen Abs baca, heb	LINE, WIT Data, I AU, LIID	ASL
SHEORAN ABHINEET S ET AL: "Stx2—specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants."  INFECTION AND IMMUNITY. JUN 2003, vol. 71, no. 6, June 2003 (2003–06), pages 3125–3130, XP002301428 ISSN: 0019–9567 page 3125, right—hand column, paragraph 2—page 3125, right—hand column, paragraph 5; figure 1  -/  *Special categories of cited documents:  *A document defining the general state of the art which is not considered to be of particular relevance. The considered to be of particular relevance which cateful or states the publication date of another which may throw doubts on priority claim(s) or which is claid to establish the publication date of another other mass.  *C document which may throw doubts on priority claim(s) or which is claim to be considered to involve an inventive step when the document of british the publication date of another other mass.  *C document referring to an oral disclosure, use, exhibition or other mass in the publication and the considered to involve an inventive step when the document of british in the publication date of another other mass in the publication date of another other mass in the publication date of another other mass.  *C document referring to an oral disclosure, use, exhibition or other mass in the publication to the international filing date but later than the priority date claimed  *C document published prior to the international filing date but later than the priority date claimed  *C document published prior to the international filing date but later than the priority date claimed  *C document published prior to the international filing date but later than the priority date claimed  *C document published prior to the international filing date but later than the priority date claimed  *C document published prior to the international filing date but later than the priority date claimed  *C document published prior to the international filing date but later than the priority date claimed  *C document p	C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT		
human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants."  INFECTION AND IMMUNITY. JUN 2003, vol. 71, no. 6, June 2003 (2003–06), pages 3125–3130, XP002301428  ISSN: 0019–9567 page 3125, right-hand column, paragraph 2 – page 3126, right-hand column, paragraph 5; figure 1  -/  *Special categories of cited documents:  *A document defining the general state of the art which is not considered to be of particular relevance  *C earlier document but published on or after the international filing date  *If document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specialcy)  *You document elefuring to an oral disclosure, use, exhibition or other special reason (as specialcy)  *Po document published prior to the international filing date but later then the priority date claimed  Date of the actual completion of the international search  19 October 2004  Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentiana 2 Nut - 2200 Pt. Rijswijk.  **Authorized officer**	Category °	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.
Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier document but published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filing date but later than the priority date claimed  "Be actual completion of the international filing date but later than the priority date claimed  "S" document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filing date but later than the priority date claimed  "Be actual completion of the international filing date but later than the priority date claimed  "Be actual completion of the international search  "Be actual completion of the international search  "Be actual completion of the international search  "Be actual completion of the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "8" document member of the same patent family  Date of mailing of the international search report  19 October 2004  Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Let (231 70) 400 0000 TV 20 551 cered.	X	human monoclonal antibodies pro against lethal infection with E coli expressing Stx2 variants.' INFECTION AND IMMUNITY. JUN 200 vol. 71, no. 6, June 2003 (2003 3125-3130, XP002301428 ISSN: 0019-9567 page 3125, right-hand column, p - page 3126, right-hand column,	otect mice Escherichia 03, 03-06), pages oaragraph 2 , paragraph	17
*A' document defining the general state of the art which is not considered to be of particular relevance  *E' earlier document but published on or after the international filing date  *L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  *O' document referring to an oral disclosure, use, exhibition or other means  *P' document published prior to the international filing date but later than the priority date claimed  *Date of the actual completion of the international search  *I' document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  *2' document member of the same patent family  Date of mailing of the international search report  *3' document member of the same patent family  Date of mailing of the international search report  *4' document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered n	X Furt	her documents are listed in the continuation of box C.	Patent family members are listed	in annex.
19 October 2004  Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel (-21 - 200 HV Rijswijk Tel (-21 - 200 HV Rijswijk)	"A" docume consider filing of the docume which citation other "P" docume of the country of the c	ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the International date ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another or other special reason (as specified) lent referring to an oral disclosure, use, exhibition or means ent published prior to the international filling date but	or priority date and not in conflict with cited to understand the principle or the invention  "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the description of particular relevance; the cannot be considered to involve an indocument is combined with one or ments, such combination being obvicin the art.	n the application but secony underlying the claimed invention of the considered to cournent is taken alone claimed invention over the step when the love of the resuch docupous to a person skilled
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel (-31 - 70) 240 200 TV 21 651 con pl				arch report
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel (31, 70) 240 200 TV 31 651 con pl	1	9 October 2004	08/11/2004	
rax. (+3 1=70) 340=3016   Stellell, 1	Name and	European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk	Authorized officer Steffen, P	

### INTERNATIONAL SEARCH REPORT

PCT/EP2004/051522

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
ategory *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MUKHERJEE JEAN ET AL: "Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli 0157:H7 infection." INFECTION AND IMMUNITY. FEB 2002, vol. 70, no. 2, February 2002 (2002-02), pages 612-619, XP002301429 ISSN: 0019-9567 page 613 - page 614; figure 1; table 1	17
<b>(</b>	MACLEOD D L ET AL: "Purification and characterization of an Escherichia coli Shiga-like toxin II variant." INFECTION AND IMMUNITY. MAY 1990, vol. 58, no. 5, May 1990 (1990-05), pages 1232-1239, XP002301430 ISSN: 0019-9567 page 1234, left-hand column, paragraph 2 paragraph 3 page 1236, left-hand column, paragraph 2; figure 4	17
X	DOWNES F P ET AL: "Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies." INFECTION AND IMMUNITY. AUG 1988, vol. 56, no. 8, August 1988 (1988-08), pages 1926-1933, XP002923370 ISSN: 0019-9567 page 1927 - page 1930; figure 7	17
X	BELISLE B W ET AL: "Monoclonal antibodies with an expanded repertoire of specificities and potent neutralizing activity for Escherichia coli heat-labile enterotoxin."  INFECTION AND IMMUNITY. DEC 1984, vol. 46, no. 3, December 1984 (1984-12), pages 759-764, XP002301431 ISSN: 0019-9567 page 759 - page 760; table 1	17
X	BELISLE B W ET AL: "Characterization of monoclonal antibodies to heat-labile enterotoxin encoded by a plasmid from a clinical isolate of Escherichia coli." INFECTION AND IMMUNITY. MAR 1984, vol. 43, no. 3, March 1984 (1984-03), pages 1027-1032, XP002301432 ISSN: 0019-9567 page 1027 - page 1028; table 1	17




Intertional Application No PCT/EP2004/051522

		PC1/EP2004/051522			
	C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT  Category Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Helevant to claim No.			
A	JEMAL C ET AL: "Analysis of Shiga toxin subunit association by using hybrid A polypeptides and site-specific mutagenesis."  JOURNAL OF BACTERIOLOGY. JUN 1995, vol. 177, no. 11, June 1995 (1995-06), pages 3128-3132, XP000669314 ISSN: 0021-9193 page 3128 - page 3129; tables 1,3	1-17			
A	MELTON-CELSA ANGELA R ET AL: "Activation of Shiga toxin type 2d (Stx2d) by elastase involves cleavage of the C-terminal two amino acids of the A2 peptide in the context of the appropriate B pentamer" MOLECULAR MICROBIOLOGY, vol. 43, no. 1, January 2002 (2002-01), pages 207-215, XP002267546 ISSN: 0950-382X page 208, right-hand column, paragraph 2 - page 210, right-hand column, paragraph 1; figures 1-3	1-17			
A	RODIGHIERO CHIARA ET AL: "Structural basis for the differential toxicity of cholera toxin and Escherichia coli heat-labile enterotoxin. Construction of hybrid toxins identifies the A2-domain as the determinant of differential toxicity" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 7, 12 February 1999 (1999-02-12), pages 3962-3969, XP002267547 ISSN: 0021-9258 page 3963, right-hand column, paragraph 3 - page 3964, right-hand column, paragraph 1; figure 1	1-17			
A	MARTIN M ET AL: "Recombinant antigen-enterotoxin A2/B chimeric mucosal immunogens differentially enhance antibody responses and B7-dependent costimulation of CD4(+) T cells."  INFECTION AND IMMUNITY. JAN 2001, vol. 69, no. 1, January 2001 (2001-01), pages 252-261, XP002231728  ISSN: 0019-9567 page 253 - page 255; figure 1	1-17			

Į





Citation of document, with indication, where appropriate of the relevant passages	Relevant to claim No.
Citation of document, with indication, where appropriate, or the relevant passages	Helevani to claim No.
JOBLING M G ET AL: "Fusion proteins containing the A2 domain of cholera toxin assemble with B polypeptides of cholera toxin to form immunoreactive and functional holotoxin-like chimeras." INFECTION AND IMMUNITY. NOV 1992, vol. 60, no. 11, November 1992 (1992-11), pages 4915-4924, XP002292263 ISSN: 0019-9567 page 4916 - page 4920	1-17
WO 01/70945 A (SIBTECH INC) 27 September 2001 (2001-09-27) figure 1; examples 1-3	1-17
WO 01/89456 A (UNIV TULANE ;CLEMENTS JOHN D (US)) 29 November 2001 (2001-11-29) figure 1; example 6.1	1–17
EP 1 057 895 A (LOHMANN ANIMAL HEALTH GMBH) 6 December 2000 (2000-12-06) paragraph '0007!; example 1	1-17
MERRITT ETHAN A ET AL: "AB-5 toxins" CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 5, no. 2, 1995, pages 165-171, XP002267548 ISSN: 0959-440X figures 1,2; table 1	1-17
PATON J C ET AL: "Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections." CLINICAL MICROBIOLOGY REVIEWS. JUL 1998, vol. 11, no. 3, July 1998 (1998-07), pages 450-479, XP002105349 ISSN: 0893-8512 page 469, right-hand column, paragraph 3 page 470, right-hand column, paragraph 3	1-17
LEBENS M ET AL: "Synthesis of hybrid molecules between heat-labile enterotoxin and cholera toxin B subunits: potential for use in a broad-spectrum vaccine." INFECTION AND IMMUNITY. JUN 1996, vol. 64, no. 6, June 1996 (1996-06), pages 2144-2150, XP002301433 ISSN: 0019-9567 the whole document	1-17
	containing the A2 domain of cholera toxin assemble with B polypeptides of cholera toxin to form immunoreactive and functional holotoxin-like chimeras."  INFECTION AND IMMUNITY. NOV 1992, vol. 60, no. 11, November 1992 (1992-11), pages 4915-4924, XP002292263  ISSN: 0019-9567 page 4916 - page 4920  W0 01/70945 A (SIBTECH INC) 27 September 2001 (2001-09-27) figure 1; examples 1-3  W0 01/89456 A (UNIV TULANE ;CLEMENTS JOHN D (US)) 29 November 2001 (2001-11-29) figure 1; example 6.1  EP 1 057 895 A (LOHMANN ANIMAL HEALTH GMBH) 6 December 2000 (2000-12-06) paragraph '0007!; example 1  MERRITT ETHAN A ET AL: "AB-5 toxins" CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 5, no. 2, 1995, pages 165-171, XP002267548 ISSN: 0959-440X figures 1,2; table 1  PATON J C ET AL: "Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections." CLINICAL MICROBIOLOGY REVIEWS. JUL 1998, vol. 11, no. 3, July 1998 (1998-07), pages 450-479, XP002105349 ISSN: 0893-8512 page 469, right-hand column, paragraph 3 - page 470, right-hand column, paragraph 3  LEBENS M ET AL: "Synthesis of hybrid molecules between heat-labile enterotoxin and cholera toxin B subunits: potential for use in a broad-spectrum vaccine." INFECTION AND IMMUNITY. JUN 1996, vol. 64, no. 6, June 1996 (1996-06), pages 2144-2150, XP002301433 ISSN: 0019-9567

# INTERNATIONAL SEARCH REPURI

Interestional Application No
PCT/EP2004/051522

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0170945	A	27-09-2001	US EP JP WO US	2001031485 A1 1268760 A1 2003533980 T 0170945 A1 2004166565 A1	18-10-2001 02-01-2003 18-11-2003 27-09-2001 26-08-2004
WO 0189456	A	29-11-2001	AU WO	7126801 A 0189456 A2	03-12-2001 29-11-2001
EP 1057895	A	06-12-2000	EP AU CN WO EP	1057895 A1 5075200 A 1357047 T 0075345 A1 1183374 A1	06-12-2000 28-12-2000 03-07-2002 14-12-2000 06-03-2002

#### INTERNATIONAL SEARCH REPORT

mational application No.

PCT/EP2004/051522

Box No. I	Nucleotide and/or amino acid sequence(s) (Continuation of Item 1.b of the first sheet)
1. With i	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed tion, the international search was carried out on the basis of:
a.	type of material  X a sequence listing table(s) related to the sequence listing
b.	format of material  X in written format  X in computer readable form
c.	time of filing/furnishing  X contained in the international application as filed  filed together with the international application in computer readable form  furnished subsequently to this Authority for the purpose of search
2. X	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Addit	tional comments: